Interestingly, significantly higher correlation of HER2 scores were found in stage IV tumors (M1 stage) compared to stage III tumors (M0 stage), although no significant differences were found between the correlation of clinicopathologic characteristics and EGFR or HER3 expression, or between HER2 expression and clinicopathologic characteristics other than tumor stage and M stage. This evidence concerns the gene ERBB3 and neoplasm.